



## Product Datasheet

<b>Product Name</b>	Tumor Necrosis Factor-Alpha Mutant Human Recombinant
<b>Cata No</b>	CB500286
<b>Source</b>	<i>Escherichia Coli.</i>
<b>Synonyms</b>	TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a, Cachectin, DIF, TNFA, TNFSF2.

### Description

The clinical use of the potent anti-tumor activity of TNF-a has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF- $\alpha$ , which binds to the murine TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF- $\alpha$  mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines *in vitro*, and exhibited lower systemic toxicity *in vivo*. Recombinant Human TNF-a Variant/Mutant compared with the wild-type, has an amino acid sequence deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect *in vivo*.

Tumor Necrosis Factor-a Variant Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 151 amino acids and having a molecular mass of 16598 Dalton.

The TNF-alpha Variant is purified by standard chromatographic techniques.

### Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder

### Biological Activity

The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is < 0.05ng/ml, corresponding to a Specific Activity of  $1 \times 10^8$  IU/mg.

### Purity

Greater than 95.0% as determined by:  
(a) Analysis by RP-HPLC.  
(b) Analysis by SDS-PAGE.

### Formulation

The protein was lyophilized after extensive dialysis against 0.5x PBS pH -7.

### Stability

Lyophilized Tumor Necrosis Factor-a Variant although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution TNF-a Variant should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

**Please prevent freeze-thaw cycles.**

### Sequence

MRKRKPVAHV VANPQAEGQL QWLNRRANAL

**\* For Non-Clinical Research Use Only \***

